| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial |
Pazopanib |
III |
372 |
Not specified |
246 |
Any |
14 PR, 164 SD, 57 PD. Median PFS 4.6 mos, OS 12.5 mos |
| Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study |
Pazopanib |
II |
211 |
2 |
211 |
Mostly second- and third-line |
0 CR, 15 PR, 38 SD. Median OS 11.1 mos, |
| Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas) |
Pazopanib, sorafenib, sunitinib |
Observational |
53 |
53 |
12: 9 pazopanib, 2 sorafenib, 1 sunitinib |
3 second-line, 4 third-line, and 5 fourth- or more lines. |
1 PR (sorafenib), 9 SD, 2 PD. Prolonged disease stabilization (12 mos): patients (pazopanib, sorafenib) |
| Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa |
Sorafenib |
Case-report |
1 |
1 |
1 |
First |
CR 7 months (then lost of follow up) |
| 1450P—systemic therapy in perivascular epithelioid cell tumors (PEComa) |
Pazopanib, sunitinib |
Observational |
49 |
49 |
4: pazopanib or sunitinib |
1–7 (no more info) |
1 PR and 2 SD, with a median PFS 7.3 mos |
| Metastatic perivascular epithelioid cell tumor of the kidney: a case report with emphasis on response to the tyrosine-kinase inhibitor sunitinib |
Sunitinib |
Case-report |
1 |
1 |
1 |
First |
SD 9 months |
| Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma |
Pazopanib |
Observational |
115 |
Not specified |
18 |
Any |
PFS 3 months, OS 14 months |
| Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety |
Apatinib |
II |
64 |
not specified |
64 |
After chemotherapy failure |
0 CR, 10 PR, 41 SD, 8 PD, median PFS 7.93 mos |
| Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California |
Pazopanib |
Observational |
123 |
1 |
123 |
Any (median number of prior lines: three) |
1 CR, 12 PR, 34 SD, 76 PD. Median PFS 3 months |
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organization for research and treatment of cancer–soft tissue and bone sarcoma group (EORTC Study 62043) |
Pazopanib |
PHASE II |
142 |
Not specified |
142 |
No more than 2 prior lines of cytotoxic treatment |
0 CR 9 PR |
| The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study |
Pazopanib |
Retrospective |
156 |
Not specified |
156 |
Any |
13 PR, 74 SD, median PFS 15.4 weeks |
